Skip to content
Featured on Startup Fame

Pharma’s real AI challenge is embedding it into daily operations, says ZS principal

The pharmaceutical and life sciences industry is past the stage of experimenting with AI in isolated projects. According to ZS, a global management consulting and technology firm, the real hurdle now is integrating AI into day-to-day operations to deliver measurable business outcomes. Karan Dhundia, Regional Managing Principal at ZS, explains why the focus has shifted from deployment to adoption and governance.

Editor, Lazyfounder

Published Updated 3 min read
Pharma’s real AI challenge is embedding it into daily operations, says ZS principal

AI adoption moves beyond pilots in pharma

Artificial intelligence is shifting from isolated pilot projects to enterprise-wide adoption in the pharmaceutical and life sciences industry, according to management consulting and technology firm ZS. The firm reports that nearly 50% of pharmaceutical companies in India are investing in AI, with 25% already implementing generative AI solutions in production environments.

Karan Dhundia, Regional Managing Principal at ZS, told EnterpriseStory that AI is now addressing critical industry questions, including drug discovery, launch optimization, physician behavior, and patient engagement. He emphasized that the technology is no longer confined to labs but is being integrated across the value chain, from research and development to commercial functions and patient experience.

Unstructured data and patient influence drive AI adoption

A key driver of AI adoption in the sector is its ability to extract value from unstructured data, which dominates healthcare. ZS estimates that AI could reduce drug discovery and development timelines by 25% to 50%. In India, the diversity of the patient base is seen as an advantage for building more representative datasets, particularly in diagnostics, clinical trial design, and patient recruitment.

Patient behavior is also accelerating AI adoption. ZS’s Future of Health Report 2026 found that 90% of people using AI and digital tools for health information trust them as much as their doctors. This shift is reshaping clinical conversations, with 68% of physicians reporting that patients now ask about specific therapies by name, nearly always informed by AI-powered sources.

The gap between AI deployment and operational integration

While AI has moved beyond the pilot phase, Dhundia noted that the industry is still transitioning from isolated use cases to enterprise-wide, governed transformation. The focus has shifted from exploring AI’s capabilities to addressing fundamental business questions, such as improving the probability of success for drug molecules, optimizing product launches, and enhancing commercial performance.

Dhundia highlighted that technology alone is insufficient for transformation. Organizations must also adapt their people, processes, and operating models to embed AI into daily decision-making. He described the current phase as a transition toward treating AI as an enterprise capability rather than a collection of experiments.

Balancing innovation and governance in a regulated industry

For AI to deliver value in pharma and life sciences, governance must evolve alongside the technology, according to Dhundia. The highly regulated nature of the industry requires that AI systems are trusted, explainable, and scalable. Governance cannot be an afterthought but must be embedded from the outset to ensure transparency, accountability, and compliance.

ZS’s approach focuses on integrating deep healthcare expertise with decision-centric AI. The firm works with clients to break down organizational silos, ensuring AI delivers end-to-end impact rather than isolated use cases. Dhundia emphasized that sustained business impact depends on adoption and scale, which requires transforming workflows and operating models beyond initial deployment.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

For founders and operators in life sciences and healthcare technology, this signals two clear realities. First, AI is no longer a competitive differentiator in the future—it is table stakes today. Companies that treat AI as a side project risk falling behind peers who are embedding it into core workflows, from R&D to commercial operations. Second, the bottleneck is shifting from technology to execution. The challenge is not whether AI can answer business questions but whether teams and processes can adapt to act on those answers. This creates opportunities for startups offering tools that bridge the gap between AI insights and operational adoption, particularly in governance, workflow integration, and change management.

Sources

  1. yourstory.com
    Pharma’s real AI challenge is embedding it into day-to-day operations: Karan Dhundia

This story is an original summary drafted with AI by Lazyfounder from the reporting listed above and checked by automated validation. Facts are attributed to their original publishers; sections marked as analysis are Lazyfounder's. Where a source is in another language, facts were machine-translated and quotations are reported, not reproduced. Read the original coverage via the links, and see our AI policy and corrections policy.

About the author

Editor, Lazyfounder

Tarun Mottlia edits LazyFounders, covering Indian startups, funding rounds, AI and product launches. Every story on the site is AI-assisted and checked against its cited sources before publication.

More stories by Tarun Mottlia

Get the LazyFounder Brief

Startup, funding and AI news in a five-minute read. Join the early-access list.

Lazy Founder - Powered by Blogy.in

Contact us

Have a story tip, correction or partnership idea?

Write to us at tarun.kumar@blogy.in or talk to the founder directly. We read every message.

Contact us